WILSON KAREN J 4

What Happened
Karen J. Wilson, a director of Serina Therapeutics, made two open-market purchases (transaction code P) totaling 10,100 shares. On June 11 she acquired 5,100 shares at approximately $1.75 per share for $8,900, and on June 12 she acquired 5,000 shares at approximately $1.77 per share for $8,850 — about $17,750 combined. These were purchases (a net inflow of shares to the insider), which some investors view as a more informative signal than routine sales.

Key Details

• Transaction dates and prices:
  • 2026-06-11: 5,100 shares @ $1.75, total $8,900 (footnote indicates weighted avg purchases ranged $1.745–$1.75)
  • 2026-06-12: 5,000 shares @ $1.77, total $8,850 (footnote indicates weighted avg purchases ranged $1.76–$1.77)
• Total purchased: 10,100 shares for ~$17,750.
• Transaction type: Open-market purchases (Code P).
• Shares owned after transaction: Not provided in the excerpt of the filing.
• Filing date: Form 4 filed 2026-06-15 (no late‑filing flag indicated in provided data).
• Footnotes: F1 and F2 state prices reflect weighted-average purchase prices across multiple trades and that the issuer or a security holder can request a breakdown by price from the reporting person.

Context
These are straightforward open-market buys by a company director. Dollar amounts are relatively modest (~$17.8k total), so while purchases can be seen as a positive signal, the size is small relative to most company market caps. No option exercises, gifts, tax-withholdings, or 10%‑owner transactions are reported in the provided excerpt.